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The north of Iran lies within the central Asian belt of oesophageal
carcinoma where the incidence is much higher than in most western
populations (Daily et al, 1996). Oesophageal carcinoma is a rapidly
progressing disease with a poor prognosis; the median survival is
less than 10 months and the 5-year survival rate is less than 10%
(Earlam et al, 1980a; Muller et al, 1990; Gaspar et al, 1997). 
Whichever therapeutic regimen is followed, the overall results
for treatment of oesophageal cancer are poor. There is no agree-
ment on the best way to manage patients with this disease.
Although, in recent decades, by improving of surgical techniques
and special care after surgery, the operational mortality has
decreased dramatically, however, the long term survival has not
improved very much (Earlam et al, 1980b). Since the effect of
surgery, radiotherapy or chemotherapy alone on survival was poor,
the combined use of radiotherapy and chemotherapy simultane-
ously or surgery with pre- or postoperative radiotherapy had been
suggested (Daily, 1996; Earlam et al, 1980a,b; Nicks et al, 1973)
but their effect on the survival is still controversial. The efficacy of
the combined modalities of radiotherapy with surgery or with
chemotherapy on the survival rate have been confirmed in several
observational studies (Parker et al, 1976; Lieberman et al, 1995;
Daily et al, 1996), but clinical trials did not consistently confirm
their effectiveness (Mei et al, 1989; Iizuka et al, 1988). 
Among the various indications of survival, the stage of malig-
nant development has been most documented (Sugimachi et al,
1983). However, the influence of the various possible prognostic
factors is complex. Survival may depend on several demographic,
clinic, pathologic, and tumour-host related variables (Sugimachi
et al, 1986). It is important that our knowledge of the prognostic
factors for such a fatal neoplasm be updated using data from
different areas in a multivariate statistical model. Such updated
information on the influence of pretreatment and treatment factors
on survival would advance the current stage of knowledge
concerning the management of oesophageal patients and hopefully
increase the time free of disease. 
The Babolsar Shahid Rajaii radiotherapy centre in the north of
Iran, has contributed to the therapeutic management of patients
with cancer of the oesophagus during the last 25 years, but no
information on survival or prognostic factors has been reported
from this area. This study aimed to study the 5-year survival of
such patients and to identify important prognostic factors. 
METHODS AND MATERIALS 
A total of 523 patients were diagnosed with oesophageal carci-
noma at the radiotherapy centre of Babolsar Shahid Rajaii between
1992 and 1996. The medical records of all these patients were
examined and information collected on potential prognostic
factors such as age, sex, area of residence, the anatomical location
of tumour, date of diagnosis, histologic type, type of treatment,
dose and frequency of radiotherapy, and size of treatment area. 
We were able to follow 230 patients for whom a postal address
was available in 1998–1999. Survival data, date of death or date last
known to be alive were obtained by writing to the families of
patients. 
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doi: 10.1054/ bjoc.2001.2153, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn the analysis, we used the nonparametric Kaplan Meier method
and the Cox regression model to study the effect of prognostic factors
on survival. In each univariate and multivariate model, we estimated
the risk ratio (RR) and its 95% confidence limits. 
RESULTS 
The mean age of the 230 patients in the study was 62( + 11) years
and modal age group 60–69 years; 59% of the patients were male.
The mean dose of radiotherapy was 4500 cGy (rads); the mean
number of sessions (frequency) 22; and the mean size of treatment
area 148 cm2. 
The survival rates (Table 1; Figure 1) were 42% at 1 year after
diagnosis, 21% at 2 years, 11% at 3 years and 8% at 5 years.
Patients under the age of 50 years survived longer than older
patients. Table 2 shows that patients aged 50–64 and over 65 years
have risk ratios of 1.73 (P = 0.03) and 1.88 (P = 0.02) compared
with patients who were under the age of 50. Table 2 and Figure 2
also show that females had significantly better survival than males
(RR = 0.71, P = 0.02) and that there was no difference in risk for
patients from rural area compared with those who were urban resi-
dents. The risk ratio represents with location of the tumour in the
middle and lower third of the oesophagus in comparison with the
upper third were 0.88 and 0.74 but the survival times were not
significantly lower than patients with tumour located in the upper
third of the oesophagus. No effect of histological type was
observed. There was a tendency for the combined modality of
radiotherapy and chemotherapy to show better survival than radio-
therapy alone (P = 0.74) but again this was not significant.
However, by increasing the of dose of radiotherapy by 100 cGY,
the risk was decreased by 1% (RR = 0.99, P = 0.05) and for each
session of radiotherapy, the risk decreased by 4% (RR = 0.96,
P = 0.0001). 
In multivariate analysis using stepwise Cox regression model,
only the effect of age and of dose and frequency of radiotherapy
remained significant. 
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Table 1 The proportion of patients with oesophageal carcinoma who survive the specified number of months from time of diagnosis with
standard errors (SE) by age group 
Age groups
Time (month) < 50 years 50–64 years > 65 years Total 
Survival rate SE Survival rate SE Survival rate SE Survival rate SE 
1 0.96 0.03 0.97 0.02 0.96 0.02 0.96 0.01 
3 0.85 0.06 0.89 0.03 0.84 0.03 0.87 0.02 
6 0.71 0.08 0.66 0.05 0.64 0.04 0.65 0.03 
9 0.50 0.09 0.50 0.05 0.54 0.05 0.52 0.03 
12 0.50 0.09 0.41 0.05 0.42 0.04 0.42 0.03 
18 0.50 0.09 0.24 0.05 0.24 0.04 0.26 0.03 
24 0.39 0.09 0.19 0.05 0.17 0.03 0.21 0.03 
30 0.36 0.09 0.15 0.04 0.11 0.03 0.15 0.02 
36 0.32 0.09 0.11 0.03 0.06 0.02 0.11 0.02 
48 0.27 0.09 0.04 0.03 0.04 0.02 0.08 0.02 
60 0.27 0.09 0.04 0.03 0.04 0.02 0.08 0.02 
Table 2 Coefficients of the Cox regression model with standard errors (SE) and the risk ratios of prognostic factors with 95%
confidence intervals (CI) and P-values from the univariate analysis 
Prognostic factors Coefficient (B) SE (B) Risk Ratio (RR) 95% CI RR P-value 
Age groups
< 50 years –– 1 ––  
50–64 years 0.55 0.25 1.73 1.06–2.82 0.03 
> 65 years 0.63 0.24 1.88 1.16–3.04 0.01 
Sex 0.53–0.94 0.02 
female vs male –0.34 0.14 0.71
Area of residence rural vs urban 0.009 0.14 1.01 0.76–1.33 0.94 
Anatomical location 
upper third –– 1 ––  
medial third –0.19 0.23 0.83 0.53–1.29 0.41 
lower third –0.29 0.23 0.74 0.47–1.17 0.20 
Histologic
SCC vs adeno 0.11 0.25 1.11 0.68–1.83 0.66 
Radiotherapy and chemotherapy vs
radiotherapy alone  0.05 0.14 1.05 0.79–1.39 0.74
Palliative vs radical 0.13 0.17 1.13 0.81–1.59 0.46 
Dose (100 rads) –0.008 0.004 0.99 0.98–1.0 0.05 
Size of surface (cm2) 0.002 0.001 1.002 1.001–1.004 0.04 
Frequency –0.035 0.008 0.96 0.94–0.98 0.001 
SCC: squamous cell carcinoma.DISCUSSION 
Our results show that overall survival rate of patients with
oesophageal carcinoma under radiotherapy at 1 and 5 years were
42% and 8% respectively. These results are consistent with those
had been reported in the western counties that the 5-year survival
was less than 10% (Daily et al, 1996; Earlam et al, 1980a,b). 
The greatest improvements the treatment of patients of the
oesophagus have occurred in China and Japan in the last decade.
For example, Chen et al (1996) in China reported that 1-year and
5-year survival of patients under radiotherapy were 64% and 23%
respectively. This improvement of survival rates, may be due to
the screening program and the treatment of patients at an early
stage of the disease. 
In this study, we found that age and gender, dose and frequency
of radiotherapy and the size of surface under radiotherapy are the
important prognostic factors for survival. Several previous studies
have also found longer survival times for women (Van Andel,
1979; Kinoshita et al, 1982; Shimada et al, 1999). Thus, the recur-
rence or progression of oesophagus carcinoma may relate to a
hormonal factor such as testosterone or androgen. Other studies,
however, have not found significant differences in survival
between men and women (Bluett et al, 1987; Koth et al, 1999;
Malhair et al, 1998; Jeremic et al, 1998). 
We observed that patients with age < 50 years had better long-
term survival than those aged > = 50 years and that the 5-year
survival at ages < 50 was 27% compared with 4% at ages > = 50; the
risk is greater for older patients, roughly 88% of the first 5 years
after diagnosis. Lund et al (1989) reported that patients at younger
ages (< = 55 years) had slightly poorer survival than older patients
(55–64); but after this age, there is an inverse relationship with
survival. In other retrospective studies, it was also demonstrated that
patients aged 65 and over had poorer survival than younger patients
(Laumous et al, 1983; Petrequin et al, 1977; Stevin et al, 1989). In
contrast, Koth et al (1999) and Giuli and Gignoux (1980) did not
observe an effect of age on survival; while, Oliver et al (1989) in a
retrospective study of 495 patients with oesophageal cancer, an
inverse association of survival time with age was observed. 
According to our results, patients with squamous cell carcinoma
had slightly poorer survival compared with adenocarcinoma in the
first year after diagnosis, but the differences between histological
types of tumour were not statistically significant. This result is also
consistent with those found in other studies (Foratiere et al, 1997;
Shwartz et al, 1999; Schahemberk et al, 1987; Lieberman et al,
1995). 
Our findings indicated that patients with tumours located in the
medial and lower third of oesophagus compared with the upper
third, tended to have slightly better survival. However, again the
differences were not statistically significant. Cederquist et al
(1978) also reported that there is no association between the
anatomical location of tumours and survival but Stevin et al (1989)
found that the 5-year survival rate for patients under radiotherapy
with anatomical location of tumour in the upper third was 15.6%
versus 3.2% for lower third. 
With regard treatment, we found that the dose and frequency of
radiotherapy and the size of surface treated appear to influence
survival. From published studies, the efficacy of radiotherapy
depends on the site and stage of the tumour and on histological type.
In particular, Giuli et al (1980) reported that for SCC of the upper
third of the oesophagus, radiotherapy had apparently better results
than resection. In general, radiotherapy is used only for those
patients who are unfit for surgery due to the their medical condition,
older age, or the presence of a tumour with nodal involvement or
invasive metastasis. There is no controlled randomized trial of radio-
therapy versus surgery for squamous cell carcinoma that evaluates
the efficacy of radiotherapy compared with surgery. Published data
indicate that the biological effect of radiation depends on the dose
and frequency and the size of surface under radiotherapy (Vincent et
al, 1993) which are consistent with those we found in this study. 
Although, many retrospective studies appear to confirm the
superiority of adjuvant radiotherapy and chemotherapy over radio-
therapy alone in improving long-term survival (Daily et al, 1996;
Lieberman et al, 1995). In our observational study, we did not find
a significant difference between the combined modality of radio-
therapy and chemotherapy versus radiotherapy alone. In observa-
tional studies, the comparison of different treatments may be
confounded by clinical indications for which it is difficult to
control. However, in a randomized clinical trial, Herskovic et al
(1992) indicated that chemotherapy in combination with radio-
therapy yields significantly better long-term survival than radio-
therapy alone (2-year survival 38% vs 10%) but that the frequency
of several life threatening side effects was higher with combined
therapy. Arauijo et al (1991) also reported that radiotherapy and
chemotherapy with 5-fluoirourcil, Miltomycin C and Bleomycin
slightly improved survival over that achievable with radiotherapy
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Figure 1. Survival of patients with oesophageal carcinoma in different age
groups 
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Figure 2. Survival of patients with oesophageal carcinoma in males and
females alone. Also, Onsuto and et al (1995) examined the effect of
combined modality therapy on advanced oesophagus carcinoma
and concluded that combined modality is the optimal way for the
management of advanced cases. 
A limitation of the present study is that we do not have data on
the staging and on spread to lymph nodes, on the size of tumour or
the depth of penetration and vascular invasion. The effect on prog-
nosis of these factors is well documented (Sugimachi et al, 1983;
Kakegaw et al, 1995). 
Another potential limitation of this study is the lack of follow-
up of some patients that work treated at the Babolsar centre. Out of
523 patients who were treated during the period of 1992–1996, we
were able to follow up 230 patients based on the availability of
their address in 1998. However, in our analysis, we did not find
any difference in the profile of prognostic factors between those
we followed up and those we did not and then our results can be
generalized for all patients who were treated within the period of
1992–1996. However, if those who had no adequate address infor-
mation were poorer that those who were traced, they may have
died sooner and so lowered the overall survival truth. 
Our results indicate that survival depends on age, sex, dose and
frequency of radiotherapy and the size of surface under radio-
therapy but the overall prognosis remains poor. For a clearer indi-
cation of the optimal way to manage patients with oesophageal
carcinoma, a multi-centred randomized clinical trial of various
combined modalities with adequate sample sizes is still necessary. 
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